Korea Investment CORP Sells 8,189 Shares of Moderna, Inc. (NASDAQ:MRNA)

Korea Investment CORP cut its holdings in Moderna, Inc. (NASDAQ:MRNA) by 5.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 154,547 shares of the company’s stock after selling 8,189 shares during the quarter. Korea Investment CORP’s holdings in Moderna were worth $6,426,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB grew its position in shares of Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after buying an additional 587 shares during the last quarter. Compass Planning Associates Inc bought a new stake in Moderna in the fourth quarter valued at $37,000. Venturi Wealth Management LLC increased its position in Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after purchasing an additional 664 shares during the period. Crowley Wealth Management Inc. bought a new position in Moderna in the 4th quarter worth $41,000. Finally, MassMutual Private Wealth & Trust FSB lifted its position in shares of Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after purchasing an additional 389 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

NASDAQ MRNA opened at $28.35 on Tuesday. Moderna, Inc. has a one year low of $26.80 and a one year high of $170.47. The stock has a 50-day moving average of $34.60 and a 200 day moving average of $43.84. The company has a market capitalization of $10.96 billion, a price-to-earnings ratio of -3.05 and a beta of 1.86.

Analyst Ratings Changes

MRNA has been the subject of a number of research reports. The Goldman Sachs Group downgraded shares of Moderna from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $99.00 to $51.00 in a research note on Wednesday, January 29th. Bank of America decreased their target price on Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research report on Tuesday, February 11th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $40.00 price target on shares of Moderna in a research note on Tuesday, February 18th. Leerink Partners lowered their price objective on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research report on Thursday, January 16th. Finally, Morgan Stanley reduced their target price on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 15th. Four research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Moderna presently has an average rating of “Hold” and a consensus target price of $59.00.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.